These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24652319)

  • 1. Clinical applications of melanoma genetics.
    Gabree M; Patel D; Rodgers L
    Curr Treat Options Oncol; 2014 Jun; 15(2):336-50. PubMed ID: 24652319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
    Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
    J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors.
    Glanz K; Volpicelli K; Kanetsky PA; Ming ME; Schuchter LM; Jepson C; Domchek SM; Armstrong K
    Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):607-14. PubMed ID: 23392000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
    Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
    Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
    Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
    [No Abstract]   [Full Text] [Related]  

  • 6. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
    Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
    Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric melanoma in melanoma-prone families.
    Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
    Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
    Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D
    Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical genetic testing for familial melanoma in Italy: a cooperative study.
    Bruno W; Ghiorzo P; Battistuzzi L; Ascierto PA; Barile M; Gargiulo S; Gensini F; Gliori S; Guida M; Lombardo M; Manoukian S; Menin C; Nasti S; Origone P; Pasini B; Pastorino L; Peissel B; Pizzichetta MA; Queirolo P; Rodolfo M; Romanini A; Scaini MC; Testori A; Tibiletti MG; Turchetti D; Leachman SA; Bianchi Scarrà G;
    J Am Acad Dermatol; 2009 Nov; 61(5):775-82. PubMed ID: 19500876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk.
    Aspinwall LG; Stump TK; Taber JM; Drummond DM; Kohlmann W; Champine M; Leachman SA
    Transl Behav Med; 2018 Jan; 8(1):29-43. PubMed ID: 29385581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
    Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
    J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
    Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
    Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
    McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
    Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of primary melanomas in an MC1R RHC homozygote/CDKN2A mutant genotype patient.
    Sinnya S; Jagirdar K; De'Ambrosis B; McMeniman E; Sturm RA; Soyer HP
    Arch Dermatol Res; 2015 Oct; 307(8):741-5. PubMed ID: 26103950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
    Mangas C; Potrony M; Mainetti C; Bianchi E; Carrozza Merlani P; Mancarella Eberhardt A; Maspoli-Postizzi E; Marazza G; Marcollo-Pini A; Pelloni F; Sessa C; Simona B; Puig-Butillé JA; Badenas C; Puig S
    Br J Dermatol; 2016 Nov; 175(5):1030-1037. PubMed ID: 27473757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Potential Melanoma Predisposition Genes in High-Risk Brazilian Patients.
    Soares de Sá BC; Moredo LF; Torrezan GT; Fidalgo F; de Araújo ÉSS; Formiga MN; Duprat JP; Carraro DM
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway.
    Levin T; Mæhle L
    Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical germline genetic testing for melanoma.
    Hansen CB; Wadge LM; Lowstuter K; Boucher K; Leachman SA
    Lancet Oncol; 2004 May; 5(5):314-9. PubMed ID: 15120668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.
    Mantelli M; Pastorino L; Ghiorzo P; Barile M; Bruno W; Gargiulo S; Sormani MP; Gliori S; Vecchio S; Ciotti P; Sertoli MR; Queirolo P; Goldstein AM; Bianchi-Scarrà G;
    Melanoma Res; 2004 Dec; 14(6):443-8. PubMed ID: 15577313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection criteria for genetic assessment of patients with familial melanoma.
    Leachman SA; Carucci J; Kohlmann W; Banks KC; Asgari MM; Bergman W; Bianchi-Scarrà G; Brentnall T; Bressac-de Paillerets B; Bruno W; Curiel-Lewandrowski C; de Snoo FA; Debniak T; Demierre MF; Elder D; Goldstein AM; Grant-Kels J; Halpern AC; Ingvar C; Kefford RF; Lang J; MacKie RM; Mann GJ; Mueller K; Newton-Bishop J; Olsson H; Petersen GM; Puig S; Rigel D; Swetter SM; Tucker MA; Yakobson E; Zitelli JA; Tsao H
    J Am Acad Dermatol; 2009 Oct; 61(4):677.e1-14. PubMed ID: 19751883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.